Bacteremia in patients receiving TNF-alpha antagonists - A prospective multicenter study

Journal of Infection

Volumn 67, Issue 6, 2013, Pages 524-528

  Loulergue, Pierre ^a   Tubach, Florence ^a,b,c   Salmon, Dominique ^a   Dellamonica, Pierre ^d   Taillan, Bruno ^e   Thorel, Jean Baptiste ^f   Marteau, Philippe ^g   Bressot, Christian ^h   Ravaud, Philippe ^a,b,c   Mariette, Xavier ⁱ   Lortholary, Olivier ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔpital Bichat   (France)

^c INSERM   (France)

^d UNIVERSITY HOSPITAL OF NICE   (France)

^e CENTRE HOSPITALIER PRINCESSE GRACE   (Monaco)

^f Service de Rhumatologie   (France)

^g HÔpital Lariboisière AP HP   (France)

^h Service de rhumatologie   (France)

ⁱ BICÊTRE HOSPITAL   (France)

Author keywords

AFSSAPS; Bacteremia; INSERM; RATIO; Rheumatoid arthritis; Staphylococcus aureus; TNF; Tumour necrosis factor (TNF) alpha antagonist

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGED; ARTICLE; BACTEREMIA; BACTEROIDES; BONE INFECTION; CLINICAL ARTICLE; DRUG WITHDRAWAL; ESCHERICHIA COLI; FEMALE; FRANCE; HUMAN; INFECTIOUS ARTHRITIS; LEGIONELLA PNEUMOPHILA; LISTERIA MONOCYTOGENES; MALE; NOCARDIA; PROGNOSIS; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SALMONELLA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS;

AFSSAPS; AGENCE FRANÇAISE DE LA SÉCURITÉ SANITAIRE DES PRODUITS DE SANTÉ; BACTEREMIA; INSERM; INSTITUT NATIONAL DE LA RECHERCHE MÉDICALE; RATIO; RECHERCHE AXÉE SUR LES BIOTHÉRAPIES; RHEUMATOID ARTHRITIS; STAPHYLOCOCCUS AUREUS; TNF; TUMOR NECROSIS FACTOR; TUMOUR NECROSIS FACTOR (TNF)-ALPHA ANTAGONIST;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, RHEUMATOID; BACTEREMIA; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84887023263     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2013.07.027     Document Type: Article

References (22)

1. Maini R., St Clair E.W., Breedveld F., Furst D., Kalden J., Weisman M., et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999 Dec 4, 354(9194):1932-1939.
2. Crum N.F., Lederman E.R., Wallace M.R. Infections associated with tumor necrosis factor-alpha antagonists. Medicine (Baltimore) 2005 Sep, 84(5):291-302.
3. Tubach F., Salmon D., Ravaud P., Allanore Y., Goupille P., Breban M., et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009 Jul, 60(7):1884-1894.
4. Keane J., Gershon S., Wise R.P., Mirabile-Levens E., Kasznica J., Schwieterman W.D., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001 Oct 11, 345(15):1098-1104.
5. Dixon W.G., Hyrich K.L., Watson K.D., Lunt M., Galloway J., Ustianowski A., et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010 Mar, 69(3):522-528.
6. Pena-Sagredo J.L., Hernandez M.V., Fernandez-Llanio N., Gimenez-Ubeda E., Munoz-Fernandez S., Ortiz A., et al. Listeria monocytogenes infection in patients with rheumatic diseases on TNF-alpha antagonist therapy: the Spanish Study Group experience. Clin Exp Rheumatol 2008 Sep-Oct, 26(5):854-859.
7. Tubach F., Ravaud P., Salmon-Ceron D., Petitpain N., Brocq O., Grados F., et al. Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-alpha antagonists. Clin Infect Dis 2006 Nov 15, 43(10):e95-100.
8. Listing J., Strangfeld A., Kary S., Rau R., von Hinueber U., Stoyanova-Scholz M., et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005 Nov, 52(11):3403-3412.
9. Kroesen S., Widmer A.F., Tyndall A., Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxf) 2003 May, 42(5):617-621.
10. Klareskog L., van der Heijde D., de Jager J.P., Gough A., Kalden J., Malaise M., et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004 Feb 28, 363(9410):675-681.
11. Dixon W.G., Watson K., Lunt M., Hyrich K.L., Silman A.J., Symmons D.P. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006 Aug, 54(8):2368-2376.
12. Bongartz T., Sutton A.J., Sweeting M.J., Buchan I., Matteson E.L., Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006 May 17, 295(19):2275-2285.
13. Curtis J.R., Patkar N., Xie A., Martin C., Allison J.J., Saag M., et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007 Apr, 56(4):1125-1133.
14. Keystone EC. Does anti-tumor necrosis factor-{alpha} therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis?: a review of long term data. J Rheumatol May 15.
15. Yamada K., Yoshino K., Sekikawa K., Madarame H., Yagita H., Nakane A. Effect of a matrix metalloproteinase inhibitor on host resistance against Listeria monocytogenes infection. FEMS Immunol Med Microbiol 2000 Nov, 29(3):187-194.
16. Hinshaw L.B., Emerson T.E., Taylor F.B., Chang A.C., Duerr M., Peer G.T., et al. Lethal Staphylococcus aureus-induced shock in primates: prevention of death with anti-TNF antibody. J Trauma 1992 Oct, 33(4):568-573.
17. Schneeweiss S., Setoguchi S., Weinblatt M.E., Katz J.N., Avorn J., Sax P.E., et al. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 2007 Jun, 56(6):1754-1764.
18. Askling J., Dixon W. The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. Curr Opin Rheumatol 2008 Mar, 20(2):138-144.
19. Galloway J.B., Hyrich K.L., Mercer L.K., Dixon W.G., Fu B., Ustianowski A.P., et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxf) Jan 2011, 50(1):124-131.
20. Askling J., Fored C.M., Brandt L., Baecklund E., Bertilsson L., Feltelius N., et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007 Oct, 66(10):1339-1344.
21. Dixon W.G., Symmons D.P., Lunt M., Watson K.D., Hyrich K.L., Silman A.J. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 2007 Sep, 56(9):2896-2904.
22. Bassetti S., Wasmer S., Hasler P., Vogt T., Nogarth D., Frei R., et al. Staphylococcus aureus in patients with rheumatoid arthritis under conventional and anti-tumor necrosis factor-alpha treatment. J Rheumatol 2005 Nov, 32(11):2125-2129.